Navigation Links
Protein key to growth of pancreatic cancer
Date:9/28/2010

The protein could provide a target to develop new treatments for the disease or enable earlier diagnosis, say the researchers from Barts and The London School of Medicine and Dentistry. Pancreatic cancer has the lowest survival rate of all cancers due to its lack of symptoms in the early stages, late diagnosis and its resistance to chemotherapy and radiation therapy.

The research funded by the Pancreatic Cancer Research Fund found that nearly three quarters of pancreatic cancer tumours had high levels of a protein known as P110γ. In laboratory experiments, when production of this protein was blocked, the cancer cells stopped growing. The findings are published online today (28 September 2010) in Clinical Cancer Research.

"It is a striking number of patients who present with high levels of P110γ," says Professor of Molecular Pharmacology, Marco Falasca, who led the research. "The fact that P110γ is needed for pancreatic cancer cells to grow shows that it is likely to have a critical role in the progression of the disease, which makes it a potential target for developing new treatments."

The team discovered the link with P110γ by screening both normal and cancerous pancreatic tissue for particular proteins linked to cell proliferation. Up to half of all cancers are linked to a member of one family of these proteins called Phosphoinositide 3-Kinase (PI3K) and the team wanted to see if a link could be made with pancreatic cancer.

Results from the screening show that high levels of P110γ were seen in 72 percent of the cancerous tissue while none could be found in the normal corresponding tissue. And when the researchers blocked production of the P110γ protein, the cancer cells stopped growing. Blocking other members of the same family had no effect, demonstrating a key role for P110γ in the progression of the disease.

"We also found that P110γ is present at high levels in patients with inflammation of the pancreas," adds co-researcher Dr Charlotte Edling.

"Patients with this condition have an increased risk of developing pancreatic cancer so this indicates that P110γ may be involved at an early stage of the disease. We now need to investigate the link between inflammation and cancer of the pancreas in more detail. Hopefully, this could provide a way to enable earlier diagnosis or to assess disease progression."

The team are now working on further research also funded by the Pancreatic Cancer Research Fund looking at whether P110γ is linked to pancreatic cancer's resistance to chemotherapy and whether genetic regulation can explain why P110γ is found at high levels in pancreatic cancer.

Maggie Blanks, CEO of the Pancreatic Cancer Research Fund said: "These initial results are very positive, but there is clearly a lot of further research required. We're pleased to be funding further work by Professor Falasca and his team to help them build on these findings."


'/>"/>

Contact: Patrick Carpenter
p.r.carpenter@qmul.ac.uk
44-020-782-23004
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. Nonstick coating of a protein found in semen reduces HIV infection
2. Protein clamps tight to telomeres to help prevent aging ... and support cancer
3. Protein clamps tight to telomeres to help prevent aging...and support cancer
4. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
5. Function found for Alzheimers protein
6. Misfolded neural proteins linked to autism disorders
7. Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out
8. Researchers zero in on protein that destroys HIV
9. Munich researchers demonstrate rocking movement in the anti-stress protein Hsp90
10. Rheumatoid arthritis signaling protein reverses Alzheimers disease in mouse model
11. Researchers find function of proteins that can enhance the progression of viruses and cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... solutions, announces today the availability of its latest software release, NetZoomDC 14.5. ... management and optimization, providing new analytical capabilities that assess complex capacity factors ...
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, ... Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s ... by randomly surveying physicians and medical leadership across the country. These select individuals ...
(Date:4/28/2016)... ... 2016 , ... SyncDog, Inc. , the leading ISV ... workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference in San Francisco, ... 6th Mobile First Conference and will feature immersive training, collaboration, and connections with ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology: